Vaxcyte, Inc. S-8, filed Feb 24, 2026: EX-FILING FEES
| Calculation of Filing Fee Tables | |||
| S-8 | |||
| Vaxcyte, Inc. | |||
| Table 1: Newly Registered Securities |
|---|
| Security Type |
Security Class Title |
Fee Calculation Rule |
Amount Registered |
Proposed Maximum Offering Price Per Unit |
Maximum Aggregate Offering Price |
Fee Rate |
Amount of Registration Fee | |
|---|---|---|---|---|---|---|---|---|
| 1 | Equity | Common Stock, par value $0.001 per share, 2020 Equity Incentive Plan | Other | 6,552,942 | $ 53.96 | $ 353,596,750.32 | 0.0001381 | $ 48,831.71 |
| 2 | Equity | Common Stock, par value $0.001 per share, 2020 Employee Stock Purchase Plan | Other | 1,310,588 | $ 53.96 | $ 70,719,328.48 | 0.0001381 | $ 9,766.34 |
| Total Offering Amounts: |
$ 424,316,078.80 |
$ 58,598.05 | ||||||
| Total Fee Offsets: |
$ 0.00 | |||||||
| Net Fee Due: |
$ 58,598.05 | |||||||
| Offering Note |
| 1 |
Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement shall also cover any additional shares of common stock, par value $0.001 per share ("Common Stock"), of Vaxcyte, Inc. (the "Registrant") that become issuable by reason of any stock dividend, stock split, recapitalization or any other similar transaction effected without receipt of consideration which results in an increase in the number of outstanding shares of Common Stock. Estimated in accordance with Rules 457(c) and 457(h) solely for purposes of calculating the registration fee on the basis of $53.96, the average of the high and low prices of the Registrant's Common Stock as reported on The Nasdaq Global Stock Market on February 17, 2026. Represents an automatic annual increase to the shares of Common Stock reserved for issuance equal to 5% of the total number of shares of Common Stock outstanding on December 31 of the preceding calendar year, which annual increase is provided by the Registrant's 2020 Equity Incentive Plan. | ||||||
| | |||||||
| 2 |
Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement shall also cover any additional shares of common stock, par value $0.001 per share ("Common Stock"), of Vaxcyte, Inc. (the "Registrant") that become issuable by reason of any stock dividend, stock split, recapitalization or any other similar transaction effected without receipt of consideration which results in an increase in the number of outstanding shares of Common Stock. Estimated in accordance with Rules 457(c) and 457(h) solely for purposes of calculating the registration fee on the basis of $53.96, the average of the high and low prices of the Registrant's Common Stock as reported on The Nasdaq Global Stock Market on February 17, 2026. Represents an automatic annual increase to the shares of Common Stock reserved for issuance equal to 1% of the total number of shares of Common Stock outstanding on December 31 of the preceding calendar year, which annual increase is provided by the Registrant's 2020 Employee Stock Purchase Plan. | ||||||
| | |||||||
| Table 2: Fee Offset Claims and Sources |
|---|
| Registrant or Filer Name | Form or Filing Type | File Number | Initial Filing Date | Filing Date | Fee Offset Claimed | Security Type Associated with Fee Offset Claimed | Security Title Associated with Fee Offset Claimed | Unsold Securities Associated with Fee Offset Claimed | Unsold Aggregate Offering Amount Associated with Fee Offset Claimed | Fee Paid with Fee Offset Source | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rule 457(p) | |||||||||||||
| Fee Offset Claims | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| Fee Offset Sources | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |